Prominent Research Scientist at Wayne State University School of Medicine
Announces Positive Results for Anti-Inflammatory Properties of Health
Enhancement Products, Inc. Proalgazyme(R) Compound
DETROIT, Nov. 3, 2009 (GLOBE NEWSWIRE) -- Professor of Pathology Dr. Fazlul
Sarkar, conducting tests at Wayne State University School of Medicine, advised
Health Enhancement Products, Inc. (OTCBB:HEPI) principals that results point to
effective and significant management of inflammation at the cellular level
without stimulating undesirable side effects.
"This may be a breakthrough in the management of inflammation, whether that
inflammation is caused by metabolic issues, injury or disease. There are few, if
any, anti-inflammatory bioactive compounds that exhibit a similar range of
desirable benefits with little or no measurable unwanted side effects," states
Fazlul Sarkar, Ph.D. "We're looking forward to conducting additional tests to
study further the anti-inflammatory properties exhibited by the ProAlgaZyme(R)
product."
The tests were conducted using human cells in culture which were then exposed to
an array of stimulants. In some of the tests, cellular secretions were then
drawn off and analyzed for anti-inflammatory activity, while in others proteins
were extracted for assessment. ProAlgaZyme(R) is a proprietary bioactive
compound developed and owned by Health Enhancement Products, Inc. which has
completed a series of comprehensive tests and assays as part of its intellectual
property development initiative which has resulted in a number of new patent
applications.
The results, although characterized as preliminary until a formal paper is
presented for peer review, point to significant and marked inhibition of certain
inflammatory processes at the cellular level. The Company continues to protect
its intellectual property by filing patent applications and taking other steps
to ensure that the value of its intellectual property is maximized. Once patent
applications are completed over the next several weeks, the Company will
disclose additional information relevant to these test results.
Peter Vitulli, Interim CEO of Health Enhancement Products commented, "As I have
previously stated, we have continued to conduct additional tests on our lead
bioactive compound, ProAlgaZyme(R). Dr. Sarkar's study is truly remarkable and
can lead to numerous opportunities for the Company. Given the tremendous
sensitivity to protecting our assets, we have asked Dr. Sarkar to withhold
specific results while we complete our official patent filing. Mr. Vitulli
continued, "As a result of these recent developments, coupled with additional
testing which continues, the Company will host a conference call upon completing
the filing of the patents to discuss this and other recent developments. Based
on current information and timing, we expect to hold the conference call later
this month with additional details to follow."
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB:HEPI) is a health & wellness company
engaged in the development of dietary supplements and food additives comprised
of pure, all-natural compounds. The Company's product is ProAlgaZyme(R)
(PAZ(TM)), a liquid product drawn from living algae grown in purified water. The
water in which the algae are grown is drawn off, filtered and bottled under the
trademark ProAlgaZyme.
About Dr. Fazlul Sarkar
Dr. Fazlul Sarkar is Professor of Pathology, Department of Pathology, Karmanos
Cancer Center at Wayne State University School of Medicine; author of scientific
papers on cancer chemoprevention, inflammation management; Senior Editor for
Molecular Cancer Therapeutics journal and also holds patents relating to
discoveries in cancer research.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press
release contain forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These forward-looking statements involve risks and uncertainties. A number
of factors could cause actual results to differ from those indicated in the
forward-looking statements, including the timing of completion of a trial,
actual future clinical trial results being different than the results the
company has obtained to date, and the company's ability to secure funding. Such
statements are subject to a number of assumptions, risks and uncertainties.
Readers are cautioned that such statements are not guarantees of future
performance and those actual results or developments may differ materially from
those set forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements, whether as a
result of new information or otherwise.
For more information, please visit http://www.heponline.com.
-0-
CONTACT: Health Enhancement Products, Inc.
IR Contact:
Howard Gostfrand/David Sasso
305.918.7000
info@amcapventures.com
www.amcapventures.com
